iSpecimen Inc. Income Tax Examination, Penalties and Interest Expense
iSpecimen Inc. (ISPC) reported Income Tax Examination, Penalties and Interest Expense of $1.25 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-08-14
- iSpecimen Inc. income tax examination, penalties and interest expense for the quarter ending 2026-06-30 was $0.00.
- iSpecimen Inc. income tax examination, penalties and interest expense for the quarter ending 2026-03-31 was $1.25K, a 93.24% decline year-over-year.
- iSpecimen Inc. income tax examination, penalties and interest expense for the quarter ending 2025-12-31 was $1.12K.
- iSpecimen Inc. income tax examination, penalties and interest expense for the quarter ending 2025-09-30 was -$2.07K.
- iSpecimen Inc. income tax examination, penalties and interest expense for fiscal 2025 was $7.97K, a 82.79% decline from fiscal 2024.
- iSpecimen Inc. income tax examination, penalties and interest expense for fiscal 2024 was $46.30K, a 78.44% decline from fiscal 2023.
- iSpecimen Inc. income tax examination, penalties and interest expense for fiscal 2023 was $214.78K.
| Period end | Income Tax Examination, Penalties and Interest Expense 3 month | Income Tax Examination, Penalties and Interest Expense 6 month | Income Tax Examination, Penalties and Interest Expense 9 month | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.25K 10-Q · filed 2026-08-14 | $2.37K derived: sum of 3 quarters · filed 2026-08-14 | $302.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.25K 10-Q · filed 2026-05-18 | $2.37K derived: sum of 2 quarters · filed 2026-05-18 | $302.00 derived: sum of 3 quarters · filed 2026-05-18 | -$9.32K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.12K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$951.00 derived: sum of 2 quarters · filed 2026-04-01 | -$10.57K derived: sum of 3 quarters · filed 2026-08-14 | $7.97K 10-K · filed 2026-04-01 |
| 2025-09-30 | -$2.07K 10-Q · filed 2025-11-17 | -$11.69K derived: sum of 2 quarters · filed 2026-08-14 | $6.85K 10-Q · filed 2025-11-17 | |
| 2025-06-30 | -$9.62K 10-Q · filed 2026-08-14 | $8.92K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $18.54K 10-Q · filed 2026-05-18 | |||
| 2024-12-31 | $46.30K 10-K · filed 2026-04-01 | |||
| 2023-12-31 | $214.78K 10-K · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |